Assembly Biosciences Appoints Bridget Hopkins as CEO for European Operations, Effective December 2025
- Assembly Biosciences promotes Bridget Hopkins to CEO for European operations, effective December 18, 2025.
- Hopkins aims to enhance product offerings and integrate talent, data, and technology for growth in Europe.
- The agency's B Corp certification reflects its commitment to social responsibility and aligns with Hopkins' strategic vision.
Assembly Biosciences Names Bridget Hopkins as CEO for European Operations
Assembly Biosciences, a prominent player in the global omnichannel media landscape within the Stagwell network, announces the promotion of Bridget Hopkins to the role of CEO for its European operations, effective December 18, 2025. Based in London, Hopkins transitions from her recent position as Chief Operating Officer, where she played a critical role in driving the agency's growth and operational excellence since joining as Managing Partner in September 2023. Her appointment is strategically significant as Assembly aims to enhance its product offerings and performance across the diverse and complex European market.
Hopkins' extensive experience in the industry positions her well to navigate the regulatory and cultural challenges facing clients in Europe. Known for her ability to forge strong partnerships and deliver integrated solutions, she emphasizes the importance of a client-centered approach. Global CEO Rick Acampora commends her operational rigor and commercial acumen, highlighting that these qualities are vital for accelerating Assembly's growth in the region. As she steps into her new role, Hopkins expresses her commitment to unlocking scalable growth by effectively integrating talent, data, and technology, ensuring that Assembly remains at the forefront of industry innovation.
In her vision for Assembly's future in Europe, Hopkins underscores the agency's core values, which resonate throughout the organization: "show up, make change, win well." By leveraging the STAGE Experience Engine and ongoing investments in innovation, she aims to deliver greater impact for clients amid a rapidly evolving media landscape. Her leadership is expected to build on Assembly's recent transformations, including expansion into new markets and the integration of advanced digital commerce capabilities, ultimately reinforcing the agency's status as a leading media partner for brands across Europe and the UK.
In addition to her new role, Hopkins brings a wealth of experience from her time as Global Client Lead at Wavemaker, where she managed complex multi-market engagements for well-known brands like Estee Lauder. Her track record of enhancing client experiences positions her to effectively lead Assembly's European strategy.
Furthermore, Assembly’s recent achievement of B Corp certification reflects its commitment to social and environmental responsibility alongside business success, indicating a forward-thinking approach that aligns with Hopkins’ strategic vision for the agency. This promotion marks a pivotal moment for Assembly, as it seeks to harness the full potential of its talent and technology to navigate the challenges of the European media landscape.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…